Hims & Hers Stock (HIMS) Surged 13.5% — Could More Gains Be Ahead?

Shares of Hims & Hers Health HIMS +13.50% ▲ were up by 13.5% on Monday. The surge came after comments from Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. on the Joe Rogan Experience podcast, where he discussed plans to make peptides more widely available. This could be a potential tailwind for HIMS, as the company may see higher demand for its products or easier market entry for related therapies. Looking ahead, analysts rate HIMS stock as Hold due to regulatory hurdles and a cautious outlook. However, the average price target suggests over 60% upside, since shares are down roughly 50% year-to-date.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

For context, Hims & Hers Health provides accessible healthcare products and services, including prescription medications, wellness products, and online medical consultations.

A Regulatory Relief for HIMS?

On the podcast, RFK Jr. said he’s eager to make about 14 peptides more accessible, including allowing them to be compounded, and noted that the FDA (Food and Drug Administration) is reviewing the science behind these treatments.

If the FDA takes a more flexible approach, it could open up big opportunities for Hims, since peptides could see wider demand and sales growth. Regulations have been a major challenge for Hims in 2026, but these comments—and the market’s reaction—could signal that the situation is starting to change.

Notably, peptides are short chains of amino acids that help regulate body processes and are used in popular GLP-1 drugs for diabetes and weight loss.

What Lies Ahead for HIMS?

HIMS stock is off to a rough start in 2026, weighed down by a sluggish Q4 earnings report and legal challenges. Adding to the concerns, analysts have turned more cautious on HIMS stock. Several lowered their price targets after the company’s Q4 results, pointing to limited details around its weight-loss business as a key reason.

Hims, best known for its weight-loss offerings, has said it plans to reduce its reliance on compounded GLP-1 sales in the U.S. However, this shift will take time. At the same time, Hims is dealing with rising costs tied to its U.S. operations and its expansion into eight international markets, including the UK and Australia. Those added expenses are raising questions about whether the company can deliver on its growth targets in the near term.

Looking ahead, investors are waiting to see meaningful progress on Hims’ international expansion, especially as profit margins remain under pressure. But with the stock sharply lower this year, many investors may be losing patience and looking for clearer signs of a turnaround.

Is HIMS Stock a Good Buy?

Overall, Wall Street analysts have a Hold consensus rating on HIMS stock based on two Buys, nine Holds, and two Sells assigned in the last three months. The average HIMS stock price target of $26.57 implies an upside of 61.23% from the current trading level.

Disclaimer & DisclosureReport an Issue